Deal facts
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Announced
- 18 November 2026
- Status
- Possible offer
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, earn-out
Sources
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that it delivered a preliminary proposal for a business combination with Alpha AI Biotech Group on October 29, 2026. Alpha acknowledged and accepted the proposal in principle on October 30, 2026. The proposal is a nonbinding expression of interest, apart from its confidentiality provisions, a limited standstill and a funding acknowledgment.
The proposal values Alpha at $600 million pre-money equity, payable in 60,000,000 ordinary shares of the company at $10.00 per share. Alpha shareholders could also receive up to 30,000,000 additional ordinary shares as earn-out consideration. These would come in two equal tranches tied to share-price thresholds of $12.50 and $15.00 during the 24 months after closing. The $600 million figure is the share-based base consideration and excludes the earn-out, which is contingent.
On November 3, 2026, the company's board approved the proposal's limited 30-day standstill, which expires on or about December 3, 2026 unless extended or terminated earlier. The standstill restricts only the consummation of a competing transaction and does not stop either party from evaluating or negotiating alternatives. The board said its approval of the standstill is not approval of any business combination. The filing also notes that Alon Izidor Tal is chief executive officer of the company's convertible note investor, Tal Alpha Yezum Vekidum Asakim (2003) Ltd., and a director of Alpha, and that Tal acknowledged the proposal on Alpha's behalf. The all-independent board was aware of both relationships when it approved the standstill.
The proposal remains subject to, among other things, satisfactory due diligence, audited financial statements, execution of definitive agreements, and required board, shareholder and regulatory approvals. No definitive agreement has been signed. Separately, the investor funded a further $250,000 on November 6, 2026, bringing funded convertible note financing to $700,000 of a $1,400,000 commitment. The funded notes are to be consolidated into a single $700,000 note maturing June 30, 2027, which, upon completion of a business combination, may be converted at the investor's option into shares of the combined entity at a 35% discount to the market price at the time of conversion. The investor's funding commitment is not contingent on approval or closing of the Alpha transaction.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Possible offer
Drugs Made In America Acquisition II Corp. offer to acquire Alpha AI Biotech Group
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed in the Current Reports on Form 8-K filed on March 17, 2026 and April 3, 2026, Drugs Made in America Acquisition II Corp. (the "Company") and Tal Alpha Yezum Vekidum Asakim (2003) Ltd. (the "Investor") are parties to the Definitive Investment and Spon
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
New Horizon Pharma B.V. to acquire Phatebo GmbH
ZeroStack Corp. disclosed in a Form 8-K, accepted by the SEC on 9 November 2026, that on 3 November 2026 it signed a Share Purchase and Transfer Agreement with New Horiz…
- Buyer
- New Horizon Pharma B.V.
- Target
- Phatebo GmbH
- Deal value
- EUR 2,150,000
- Deal type
- strategic acquisition
Buyer history
Drugs Made In America Acquisition II Corp.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive